Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 5, 2021

Primary Completion Date

November 2, 2021

Study Completion Date

December 13, 2021

Conditions
Generalized Myasthenia Gravis
Interventions
BIOLOGICAL

efgartigimod PH20 SC

Subcutaneous injection with efgartigimod PH20 SC

BIOLOGICAL

efgartigimod IV

Intravenous infusion of efgartigimod

Trial Locations (47)

1082

Investigator site 15 - HU0360013, Budapest

2333

Investigator Site 7 - NL0310001, Leiden

4032

Investigator Site 16 - HU0360020, Debrecen

9000

Investigator site 5 - BE0320007, Ghent

10117

Investigator Site 30 - DE490006, Berlin

14226

Investigator Site 11 - US0010111, Amherst

20133

Investigator Site 17 - IT0390003, Milan

27514

Investigator Site 40 - US0010003, Chapel Hill

27710

Investigator Site 38 - US0010077, Durham

28046

Investigator Site 25 - ES0340002, Madrid

30912

Investigator Site 47 - US0010113, Augusta

33428

Investigator site 2 - US0010108, Boca Raton

33952

Investigator site 1 - US0010110, Port Charlotte

38018

Investigator site 4 - US0010008, Cordova

41076

Investigator Site 27 - US0010006, Tampa

44195

Investigator Site 43 - 0010019, Cleveland

46026

Investigator Site 10 - ES0340039, Valencia

48149

Investigator Site 29 - DE490009, Münster

66205

Investigator Site 42 - US0010015, Kansas City

78229

Investigator Site 46 - US0010009, Texas City

78756

Investigator Site 28 - US0010066, Austin

92011

Investigator site 2 - US0010032, Carlsbad

92868

Investigator Site 41 - US0010004, Orange

194354

Investigator Site 36 - RU0070014, Saint Petersburg

630087

Investigator Site 35 - RU0070002, Novosibirsk

0112

Investigator site 13 - GE9950002, Tbilisi

0114

Investigator site 12 - GE9950001, Tbilisi

Investigator site 14 - GE9950003, Tbilisi

0160

Investigator Site 44 - GE9950004, Tbilisi

Investigator Site 45 - GE9950016, Tbilisi

00189

Investigator Site 39 - IT0390008, Roma

063-0005

Investigator Site 31 - JP0810055, Sapporo

260-8677

Investigator Site 18 - JP0810002, Chiba

025-0082

Investigator site 6 - JPN0810004, Hanamaki

0810058

Investigator Site 33 - JP0810058, Hiroshima

565-0871

Investigator Site 19 - JP0810007, Osaka

983-8520

Investigator Site 34 - JP0810005, Sendai

143-8541

Investigator Site 32 - JP0810059, Tokyo

160-0023

Investigator Site 20 - JP0810009, Tokyo

80-952

Investigator Site 21 - PL0480001, Gdansk

40-123

Investigator Site 8 - PL0480007, Katowice

31-2002

Investigator Site 9 - PL0480024, Krakow

31-505

Investigator Site 22 - PL0480005, Krakow

20-093

Investigator Site 23 - PL0480018, Lublin

02-097

Investigator Site 24 - PL0480022, Warsaw

08035

Investigator Site 37 - ES0340021, Barcelona

08041

Investigator Site 26 - ES0340038, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY